Back to search results

Study of Rina-S for Non-Small Cell Lung Cancer

This study is testing a drug called Rina-S for people with non-small cell lung cancer (NSCLC) that has spread or cannot be removed by surgery or radiation. You might be able to join if your cancer has gotten worse after previous treatments. The main goal is to see how many people respond to Rina-S, meaning their cancer shrinks or stops growing. All participants will receive Rina-S as an intravenous (IV) infusion, meaning it's given directly into your vein. This is a Phase 2 study, meaning it's still in an earlier stage of testing, and it plans to enroll about 240 people worldwide. The study is currently open, but its exact status is unclear.

Study design
This is a Phase 2, open-label study, meaning both you and your doctors will know you are receiving Rina-S. It plans to enroll about 240 participants.
What's involved
You will receive Rina-S as an IV infusion. You will attend 1 to 5 visits at the study clinic every 3 weeks, and treatment may last an average of 12 months or longer if your cancer responds well.
Compensation
Not stated in the trial record.
Follow-up
The main outcome of the study, how well Rina-S works, will be measured for approximately 3 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07288177

Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer

Recruiting
PHASE2Ages 18+InterventionalTreatment
Genmab
~240 participants
Updated 2026-08-26 on ClinicalTrials.gov
What's tested:Rina-S

At a glance

Recruiting sites
74 of 74 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 as Assessed by Investigator
Measured over Approximately 3 years

Conditions

Non-small Cell Lung Cancer (NSCLC)

Explore related trials

Lung Non-Small Cell Carcinoma

Where it's being run

74 sites across 31 states
Spain11
Australia6
France5
Taiwan5
China4
Poland4
California3
Oregon3

Study leadership

  • Study Official · STUDY_DIRECTOR · Genmab

Who to contact

Genmab Trial Information
[email protected]
+4570202728
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Participant has histologically or cytologically confirmed metastatic or locally advanced NSCLC of adenocarcinoma histology, not amenable to curative surgery or radiotherapy.
Participant must have radiological disease progression while on or after receiving the most recent regimen.
Participants either may have actionable genetic alterations (AGAs) or no AGAs.
Participant has measurable disease according to RECIST v1.1.
Participant has an Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score of 0 or 1 within 7 days of Cycle 1 Day 1.

Exclusion

Participant has NSCLC with histology other than adenocarcinoma
Participant has a past or current malignancy other than the inclusion diagnosis before the planned first dose of trial treatment, or any evidence of residual disease from a previously diagnosed malignancy. Exceptions are malignancies with a negligible risk of metastasis or death (eg, 5-year OS ≥ 90%), including, but not limited to, adequately treated cervical carcinoma of stage 1B or less, in situ basal cell or squamous cell skin carcinoma, in situ bladder cancer, ductal carcinoma in situ, or any past malignancy considered cured for ≥ 3 years.
Participants with newly identified or known unstable (eg, progressing brain metastases) or symptomatic central nervous system (CNS) metastases or history of carcinomatous meningitis (also known as leptomeningeal disease). Participants with history of spinal cord compression (from disease). Participants with previous CNS-directed therapy (eg, radiotherapy and/or surgery) for brain metastases may participate provided lesion(s) are radiologically stable (ie, without evidence of progression) for at least 28 days by repeat imaging.

What this trial measures

  • Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 as Assessed by InvestigatorApproximately 3 years